TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00926367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin and benzoyl peroxide
Description: Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl peroxide 2.5% and adapalene 0.1% gel
Description: Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
Study: NCT02414763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teachable Moment Brief Intervention
Description: functional analysis, collaborative interpersonal style
Study: NCT02296918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Participants will receive oral acalabrutinib in Cohorts 1, 2, 3, and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Participants will receive oral acalabrutinib in Cohorts 1, 2, 3, and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Participants will receive oral acalabrutinib in Cohorts 1, 2, 3, and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: Participants will receive oral acalabrutinib in Cohorts 1, 2, 3, and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive intravenous obinutuzumab in Cohorts 1, 2, and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive intravenous obinutuzumab in Cohorts 1, 2, and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive intravenous obinutuzumab in Cohorts 1, 2, and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive oral venetoclax in Cohorts 3 and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive oral venetoclax in Cohorts 3 and 4. The details are mentioned in the cohort description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive intravenous rituximab in Cohort 3. The details are mentioned in the cohort description.
Study: NCT03815643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
Study: NCT01242228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor
Description: oral
Study: NCT01427322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: given orally 2-4 hours before first fraction of radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Standard radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Standard radiation therapy
Study: NCT00869427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin C
Description: vitamin C 1g bid for 1 year
Study: NCT03031535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide acetate
Description: Intranasal spray of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide acetate
Description: Intranasal spray of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide acetate
Description: Intranasal spray of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide acetate
Description: Intranasal spray of octreotide acetate
Study: NCT00468338

Intervention type: DEVICE
Intervention: BIS monitor
Description: BIS monitor measures the depth of anesthesia and was used in the entire group
Study: NCT03031535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide acetate
Description: Intranasal spray of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal octreotide acetate
Description: Intranasal spray of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide acetate
Description: Subcutaneous injectable solution of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide acetate
Description: Subcutaneous injectable solution of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide acetate
Description: Subcutaneous injectable solution of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide acetate
Description: Subcutaneous injectable solution of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide acetate
Description: Subcutaneous injectable solution of octreotide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide acetate
Description: Subcutaneous injectable solution of octreotide acetate

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing hormone
Description: Part of the well established GHRH/Arginine challenge to detect GH deficiency.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing hormone
Description: Part of the well established GHRH/Arginine challenge to detect GH deficiency.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Part of the well established GHRH/Arginine challenge to detect GH deficiency.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arginine hydrochloride
Description: Part of the well established GHRH/Arginine challenge to detect GH deficiency.
Study: NCT01869725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gallium Ga 68-edotreotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo gallium Ga 68-edotreotide PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 pentetreotide
Description: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
Study: NCT03356132

Intervention type: DEVICE
Intervention: Silimed® Textured Silicone Gel-Filled Breast Implant
Description: Women undergoing primary and secondary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.

Intervention type: DEVICE
Intervention: Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
Description: Women undergoing primary and secondary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
Study: NCT01869725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo indium In 111 pentetreotide contrast-enhanced CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced magnetic resonance imaging
Description: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
Study: NCT00950911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amg 162
Description: 120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
Study: NCT02521766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmoni Modular Intraocular Lens
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmoni Modular Intraocular Lens
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag
Study: NCT03282123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: 80 to 120 mg MDMA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualized therapy
Description: Non-directive therapy conducted during MDMA-assisted therapy session
Study: NCT04004000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod
Description: The main study includes a treatment period of approximately one year. Subjects will receive 15 mg of losmapimod twice daily by mouth; for a total of 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.~Only subjects who participated in and completed all procedures for the main study (Week 60) will be eligible to participate in the extension.~For the extension, subjects will receive 15 mg of losmapimod by mouth twice daily for a total of 30 mg by mouth daily. Participation will continue until 90 days after commercial drug is available post regulatory approval or study termination.
Study: NCT01398839

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEGA UV-A Illumination System
Description: Only subjects assigned to the treatment group will receive treatment with the UV Light

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Both treatment and sham groups will receive riboflavin

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Riboflavin
Description: Both treatment and sham groups will receive riboflavin
Study: NCT04306172

Intervention type: OTHER
Intervention: An US Readmission Risk Prediction Model
Description: Logistic regression model that predicts the risk of all-cause unplanned readmissions developed by the privately held healthcare software company EPIC.
Study: NCT02521766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmoni Modular Intraocular Lens
Description: Two-component system consisting of a base and a separate optic that allows for an intraoperative exchange of the optic only without direct manipulation of the capsular bag

Intervention type: DEVICE
Group type: OTHER
Intervention: Commercially Available Intraocular Lens
Description: IOL per investigator's standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optic exchange
Description: Removal of one optic and replacement with another for the purpose of improving refractive outcomes
Study: NCT04708600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pitch Elevation Therapy
Description: Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory discrimination of lower and higher tones~* pitch glides~* pitch glides using straw phonation and resonance tube phonation~* practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pitch Elevation Therapy
Description: Goal: mean fundamental frequency of 180Hz (range 140 and 300Hz); Doses and duration: 5 one hour sessions (5h), 5 weeks~Content:~* auditory discrimination of lower and higher tones~* pitch glides~* pitch glides using straw phonation and resonance tube phonation~* practice of higher pitch voice (target: 180Hz) in isolated vowels - syllables - mono and bisyllabic words -phrases - sentences and texts - conversation (generalization to spontaneous speech)
Study: NCT03316456

Intervention type: DIAGNOSTIC_TEST
Intervention: Observational: Stool Sample Collection
Description: Observational: Stool Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner.

Intervention type: DIAGNOSTIC_TEST
Intervention: Observational: Blood Sample Collection
Description: Observational: Blood Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner.

Intervention type: DIAGNOSTIC_TEST
Intervention: Observational: Urine Sample Collection
Description: Observational: Urine Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner.
Study: NCT04523181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antroquinonol
Description: double-blind for antroquinonol and Placebo with same out-look and same frequency.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule without active compound
Study: NCT02998489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast milk advancement
Description: 30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional milk advancement
Description: 20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
Study: NCT02755922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Application of autologous mesenchymal stem cells
Description: within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
Study: NCT00928200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg/m2/day divided BID. Give by mouth days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2/day IV over 15 minutes on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Intrathecal Therapy
Description: Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
Study: NCT04071522

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03526120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pistachio
Description: Dailly 44 g unsalted pistachios snack for 12 weeks
Study: NCT01203553

Intervention type: PROCEDURE
Intervention: Abdominal surgery
Description: Intraoperative mesh implantation

Intervention type: PROCEDURE
Intervention: Abdominal surgery
Description: Intraoperative mesh implantation
Study: NCT04548622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim Rapid 2 system triggering Magstim Super Rapid system
Description: Week 1 treatment includes rTMS for 5 sessions to both the left and right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
Study: NCT03829332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for lenvatinib
Description: oral capsule
Study: NCT00964717

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: real chiropractic
Description: real chiropractic manipulation

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Chiropractic
Description: Placebo stimulation using 'activator' thumper
Study: NCT02728986

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Profore multilayer compression bandage + standard regimen for wound care according to investigator's choice

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coban2
Description: Coban2 compression system + standard regimen for wound care according to investigator's choice
Study: NCT02266420

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples of 10 mL
Description: Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples of 10 mL
Description: Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
Study: NCT00764868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate (LDX)
Description: optimal dose of 30, 50 or 70 mg once daily
Study: NCT03701464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic naso-gallbladder drainage
Description: Using ERCP technique insert a naso-gallbladder drainage tube through common bile duct and cystic duct.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous gallbladder drainage
Description: Percutaneous transhepatic technique insert drainage tube into gallbladder
Study: NCT01231282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diffusion-weighted MRI
Description: MRI scan without contrast administration and without radiation exposure
Study: NCT00597883

Intervention type: PROCEDURE
Intervention: Carotid endarterectomy
Description: (non-experimental) carotid endarterectomy (CEA) for treatment of carotid artery stenosis

Intervention type: OTHER
Intervention: Neurological and neuropsychological evaluations
Description: Clinical examinations consisting of a neurological and neuropsychological evaluation
Study: NCT02027935

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CD8+ Melanoma Specific T Cells
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04107506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Filming Interactions to Nurture Development
Description: FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Healthy Toddler Program
Description: HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.